Sitaphage Tablets 50Mg/500Mg (1 Strip = 7 Tablets)

Requires Prescription (YES/NO)

Yes

Generics

Sitagliptin, Metformin

Used For

Diabetes

How it works

By increasing and prolonging active incretin levels, Sitagliptin increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner. It is a biguanide with antihyperglycemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycemia.

Dosage

Sitagliptin, Metformin

Side Effects

Common: nausea.Uncommon: somnolence, diarrhea, upper abdominal pain and blood glucose decreased.

Drug Interactions

Digoxin , Furosemide , Nifedipine , Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine ranitidine, triamterene, trimethoprim, or vancomycin) , thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.

Indication

It is indicated as: - Initial therapy in patients with type 2 diabetes mellitus to improve glycemic control when diet and exercise do not provide adequate glycemic control. As an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus inadequately controlled on Metformin HCl or Sitagliptin alone or in patients already being treated with the combination of Sitagliptin and Metformin HCl.

When not to Use

The combination of Sitagliptin and Metformin HCl is contraindicated in:- Patients with type 1 diabetes. -Patients with known hypersensitivity to Sitagliptin, Metformin HCl or any other component of the product. - Acute or chronic metabolic acidosis , including ketoacidosis, with or without coma.

Precaution

Sitagliptin+Metformin HCl are known to be substantially excreted by the kidney.Metformin HCl-related lactic acidosis increases with the degree of insufficiency of renal function, therefore, serum creatinine concentrations should be determined regularly.

Warning 1

Since impaired hepatic function has been associated with some cases of lactic acidosis, Sitagliptin+Metformin HCl should generally be avoided in patients with clinical or laboratory evidence of hepatic disease.

Warning 2

Patient receiving Sitagliptin+Metformin HCl in combination with a sulphonylurea or with insulin may be at risk for hypoglycemia. Therefore, a reduction in the dose of the sulphonylurea or insulin may be necessary.

Warning 3

After initiation of Sitagliptin, patients should be observed carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, Sitagliptin should promptly be discontinued and appropriate management should be initiated.

Pregnancy category

Always consult your physician before using any medicine.

Storage (YES/NO)

Store this medicine at room temperature, away from direct light and heat.